David Harlan to Treatment Outcome
This is a "connection" page, showing publications David Harlan has written about Treatment Outcome.
Connection Strength
0.110
-
Khan MH, Harlan DM. Counterpoint: clinical islet transplantation: not ready for prime time. Diabetes Care. 2009 Aug; 32(8):1570-4.
Score: 0.039
-
Rother KI, Harlan DM. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest. 2004 Oct; 114(7):877-83.
Score: 0.028
-
Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, TenHoor CN, White L, Knechtle SJ, Harlan DM. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999 Jun; 5(6):686-93.
Score: 0.019
-
Blau JE, Abegg MR, Flegel WA, Zhao X, Harlan DM, Rother KI. Long-term immunosuppression after solitary islet transplantation is associated with preserved C-peptide secretion for more than a decade. Am J Transplant. 2015 Nov; 15(11):2995-3001.
Score: 0.015
-
Dy EC, Harlan DM, Rother KI. Assessment of islet function following islet and pancreas transplantation. Curr Diab Rep. 2006 Aug; 6(4):316-22.
Score: 0.008